$922.57
0.12% today
NYSE, Sep 16, 08:45 pm CET
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Eli Lilly and Company Stock price

$923.71
+15.66 1.72% 1M
+165.87 21.89% 6M
+340.79 58.46% YTD
+324.83 54.24% 1Y
+685.75 288.18% 3Y
+812.82 733.00% 5Y
+858.52 1,316.95% 10Y
NYSE, Closing price Fri, Sep 13 2024
-11.31 1.21%
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Key metrics

Market capitalization $877.92b
Enterprise Value $903.52b
P/E (TTM) P/E ratio 115.38
EV/FCF (TTM) EV/FCF 3,504.73
EV/Sales (TTM) EV/Sales 23.21
P/S ratio (TTM) P/S ratio 22.56
P/B ratio (TTM) P/B ratio 64.76
Dividend yield 0.49%
Last dividend (FY23) $4.52
Revenue growth (TTM) Revenue growth 31.87%
Revenue (TTM) Revenue $38.92b
EBIT (operating result TTM) EBIT $13.43b
Free Cash Flow (TTM) Free Cash Flow $257.80m
Cash position $3.36b
EPS (TTM) EPS $8.01
P/E forward 59.15
P/S forward 19.11
EV/Sales forward 19.66
Short interest 0.78%
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Eli Lilly and Company forecast:

26x Buy
81%
5x Hold
16%
1x Sell
3%

Analyst Opinions

32 Analysts have issued a Eli Lilly and Company forecast:

Buy
81%
Hold
16%
Sell
3%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
11,303 11,303
36% 36%
100%
- Direct Costs 2,170 2,170
20% 20%
19%
9,133 9,133
40% 40%
81%
- Selling and Administrative Expenses 1,703 1,703
9% 9%
15%
- Research and Development Expense 2,711 2,711
15% 15%
24%
4,719 4,719
82% 82%
42%
- Depreciation and Amortization 414 414
13% 13%
4%
EBIT (Operating Income) EBIT 4,304 4,304
94% 94%
38%
Net Profit 2,967 2,967
68% 68%
26%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Negative
Barrons
one day ago
Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna in the second quarter.
Positive
The Motley Fool
2 days ago
AbbVie has proved it can adapt to a fast-changing environment. Eli Lilly has a sustainable culture of growth.
Positive
Reuters
3 days ago
Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 43,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today